About: Emerging pharmacological therapies for ARDS: COVID-19 and beyond

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Emerging pharmacological therapies for ARDS: COVID-19 and beyond Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Emerging pharmacological therapies for ARDS: COVID-19 and beyond
Creator	Bellani, Giacomo Nichol, Alistair Laffey, John Mcauley, Danny Mcnicholas, Bairbre Pham, Tài Rocco, Patricia O'kane, Cecilia Curley, Ger Horie, Shahd Rezoagli, Emanuele Santos, Claudia Dos
Source	Medline; PMC
abstract	ARDS, first described in 1967, is the commonest form of acute severe hypoxemic respiratory failure. Despite considerable advances in our knowledge regarding the pathophysiology of ARDS, insights into the biologic mechanisms of lung injury and repair, and advances in supportive care, particularly ventilatory management, there remains no effective pharmacological therapy for this syndrome. Hospital mortality at 40% remains unacceptably high underlining the need to continue to develop and test therapies for this devastating clinical condition. The purpose of the review is to critically appraise the current status of promising emerging pharmacological therapies for patients with ARDS and potential impact of these and other emerging therapies for COVID-19-induced ARDS. We focus on drugs that: (1) modulate the immune response, both via pleiotropic mechanisms and via specific pathway blockade effects, (2) modify epithelial and channel function, (3) target endothelial and vascular dysfunction, (4) have anticoagulant effects, and (5) enhance ARDS resolution. We also critically assess drugs that demonstrate potential in emerging reports from clinical studies in patients with COVID-19-induced ARDS. Several therapies show promise in earlier and later phase clinical testing, while a growing pipeline of therapies is in preclinical testing. The history of unsuccessful clinical trials of promising therapies underlines the challenges to successful translation. Given this, attention has been focused on the potential to identify biologically homogenous subtypes within ARDS, to enable us to target more specific therapies ‘precision medicines.’ It is hoped that the substantial number of studies globally investigating potential therapies for COVID-19 will lead to the rapid identification of effective therapies to reduce the mortality and morbidity of this devastating form of ARDS.
has issue date	2020-07-11(xsd:dateTime)
bibo:doi	10.1007/s00134-020-06141-z
bibo:pmid	32654006
has license	no-cc
sha1sum (hex)	5b1584d718cb6789a528719033005842b97a39a3
schema:url	https://doi.org/10.1007/s00134-020-06141-z
resource representing a document's title	Emerging pharmacological therapies for ARDS: COVID-19 and beyond
has PubMed Central identifier	PMC7352097
has PubMed identifier	32654006
schema:publication	Intensive Care Med
resource representing a document's body	covid:5b1584d718cb6789a528719033005842b97a39a3#body_text
is schema:about of	named entity 'severe' named entity 'insights' named entity 'number' named entity 'effects' named entity 'hypoxemic' named entity 'develop' named entity 'patients' named entity 'ARDS' named entity 'ARDS' named entity '1967' named entity 'pleiotropic' named entity 'therapies' named entity 'PHASE' named entity 'SPECIFIC' named entity 'REMAINS' named entity 'INDUCED' named entity 'TEST' named entity 'LEAD' named entity 'SUCCESSFUL' named entity 'NEED' named entity 'ASSESS' named entity 'ACUTE' named entity 'management' named entity 'focus' named entity 'induced' named entity 'COVID-19' named entity 'potential' named entity 'testing' named entity 'focused' named entity 'advances' named entity 'successful' named entity 'testing' named entity 'pathophysiology' named entity 'pharmacological' named entity 'endothelial' named entity 'reduce' named entity 'potential' named entity 'promising' named entity 'ARDS' named entity 'ARDS' named entity 'clinical trials' named entity 'anticoagulant' named entity 'clinical studies' named entity 'pharmacological' named entity 'ARDS' named entity 'antiviral' named entity 'pro-inflammatory cytokine' named entity 'preclinical models' named entity 'elafin' named entity 'MAPK' named entity 'LPS' named entity 'protease inhibitors' named entity 'Type I interferon' named entity 'tetracycline' named entity 'community-acquired pneumonia' named entity 'type I interferon' named entity 'receptor' named entity 'heparin' named entity 'lung edema' named entity 'LPS' named entity 'lopinavir/ritonavir' named entity 'clinical studies' named entity 'heparin' named entity 'open-label' named entity 'Ulinastatin' named entity 'ARDS' named entity 'imatinib' named entity 'remdesivir' named entity 'steroids' named entity 'immunomodulatory drug'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software